SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,692.38 (-1.39%)
DOW   29,590.53 (-1.12%)
QQQ   275.10 (-1.67%)
AAPL   142.51 (-2.01%)
MSFT   241.91 (-1.98%)
META   137.00 (-1.49%)
GOOGL   99.87 (-1.53%)
AMZN   118.15 (-1.79%)
TSLA   234.49 (-1.53%)
NVDA   125.25 (-4.61%)
NIO   14.36 (-2.78%)
BABA   82.42 (-2.25%)
AMD   64.10 (-5.53%)
T   15.27 (-0.33%)
MU   53.68 (-1.72%)
CGC   3.68 (-1.87%)
F   12.19 (-1.38%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.04 (-1.12%)
PYPL   92.07 (-2.49%)
PFE   42.97 (-0.28%)
NFLX   236.00 (-1.67%)
S&P 500   3,692.38 (-1.39%)
DOW   29,590.53 (-1.12%)
QQQ   275.10 (-1.67%)
AAPL   142.51 (-2.01%)
MSFT   241.91 (-1.98%)
META   137.00 (-1.49%)
GOOGL   99.87 (-1.53%)
AMZN   118.15 (-1.79%)
TSLA   234.49 (-1.53%)
NVDA   125.25 (-4.61%)
NIO   14.36 (-2.78%)
BABA   82.42 (-2.25%)
AMD   64.10 (-5.53%)
T   15.27 (-0.33%)
MU   53.68 (-1.72%)
CGC   3.68 (-1.87%)
F   12.19 (-1.38%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.04 (-1.12%)
PYPL   92.07 (-2.49%)
PFE   42.97 (-0.28%)
NFLX   236.00 (-1.67%)
S&P 500   3,692.38 (-1.39%)
DOW   29,590.53 (-1.12%)
QQQ   275.10 (-1.67%)
AAPL   142.51 (-2.01%)
MSFT   241.91 (-1.98%)
META   137.00 (-1.49%)
GOOGL   99.87 (-1.53%)
AMZN   118.15 (-1.79%)
TSLA   234.49 (-1.53%)
NVDA   125.25 (-4.61%)
NIO   14.36 (-2.78%)
BABA   82.42 (-2.25%)
AMD   64.10 (-5.53%)
T   15.27 (-0.33%)
MU   53.68 (-1.72%)
CGC   3.68 (-1.87%)
F   12.19 (-1.38%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.04 (-1.12%)
PYPL   92.07 (-2.49%)
PFE   42.97 (-0.28%)
NFLX   236.00 (-1.67%)
S&P 500   3,692.38 (-1.39%)
DOW   29,590.53 (-1.12%)
QQQ   275.10 (-1.67%)
AAPL   142.51 (-2.01%)
MSFT   241.91 (-1.98%)
META   137.00 (-1.49%)
GOOGL   99.87 (-1.53%)
AMZN   118.15 (-1.79%)
TSLA   234.49 (-1.53%)
NVDA   125.25 (-4.61%)
NIO   14.36 (-2.78%)
BABA   82.42 (-2.25%)
AMD   64.10 (-5.53%)
T   15.27 (-0.33%)
MU   53.68 (-1.72%)
CGC   3.68 (-1.87%)
F   12.19 (-1.38%)
GE   66.01 (-0.32%)
DIS   98.75 (-1.29%)
AMC   7.04 (-1.12%)
PYPL   92.07 (-2.49%)
PFE   42.97 (-0.28%)
NFLX   236.00 (-1.67%)
NYSEAMERICAN:IBIO

iBio - IBIO Stock Forecast, Price & News

$0.16
-0.01 (-7.65%)
(As of 10/7/2022 09:15 AM ET)
Add
Compare
Today's Range
$0.15
$0.16
50-Day Range
N/A
52-Week Range
$0.15
$0.99
Volume
415 shs
Average Volume
3.19 million shs
Market Capitalization
$34.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

iBio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
855.4% Upside
$1.50 Price Target
Short Interest
Healthy
4.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.40mentions of iBio in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

IBIO stock logo

About iBio (NYSEAMERICAN:IBIO) Stock

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

iBio (NYSEAMERICAN:IBIO) Cut to "Neutral" at Cantor Fitzgerald
3 Healthcare Stocks to Sell Before They Die - InvestorPlace
Ibio earnings, Revenue miss in Q1 - Investing.com India
iBio reports FY results (NYSE:IBIO) - Seeking Alpha
iBio Q4 2022 Earnings Preview - Seeking Alpha
Here's what Wall Street expects from iBio's earnings report
See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Company Calendar

Last Earnings
11/15/2021
Today
10/07/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IBIO
Previous Symbol
NASDAQ:IBIO
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.84
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$0.17
Forecasted Upside/Downside
+855.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-23,210,000.00
Net Margins
-1,177.85%
Pretax Margin
-1,177.96%

Debt

Sales & Book Value

Annual Sales
$2.37 million
Book Value
$0.50 per share

Miscellaneous

Free Float
214,457,000
Market Cap
$34.25 million
Optionable
Not Optionable
Beta
-3.65

Key Executives

  • Mr. Thomas F. Isett III (Age 57)
    CEO, Pres & Chairman
    Comp: $1.3M
  • Dr. Martin B. Brenner D.V.M. (Age 50)
    Ph.D., Chief Scientific Officer
    Comp: $375.95k
  • Mr. Randy Joe Maddux (Age 61)
    Strategic Advisor
    Comp: $485.2k
  • Mr. Robert B. Kay (Age 82)
    Interim Sec. & Interim Treasurer
    Comp: $150k
  • Mr. Robert Matthew Lutz (Age 53)
    Chief Financial & Bus. Officer
  • Mike Jenkins
    VP of Operations
  • Stephen Kilmer
    Investor Relations Officer
  • Mr. Marc Banjak J.D.
    Gen. Counsel
  • Ms. Lisa Middlebrook
    Chief HR Officer
  • Dr. Melissa Berquist Ph.D.
    VP and Head of Vaccines & Animal Health













IBIO Stock - Frequently Asked Questions

Should I buy or sell iBio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings
or view top-rated stocks.

What is iBio's stock price forecast for 2022?

2 Wall Street analysts have issued 1-year target prices for iBio's shares. Their IBIO share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 855.4% from the stock's current price.
View analysts price targets for IBIO
or view top-rated stocks among Wall Street analysts.

How have IBIO shares performed in 2022?

iBio's stock was trading at $0.4786 at the beginning of 2022. Since then, IBIO stock has decreased by 67.2% and is now trading at $0.1570.
View the best growth stocks for 2022 here
.

Are investors shorting iBio?

iBio saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 9,660,000 shares, a decrease of 9.1% from the August 31st total of 10,630,000 shares. Based on an average daily volume of 2,090,000 shares, the days-to-cover ratio is currently 4.6 days. Approximately 4.5% of the company's shares are short sold.
View iBio's Short Interest
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) released its earnings results on Monday, November, 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The biotechnology company earned $0.21 million during the quarter. iBio had a negative net margin of 1,177.85% and a negative trailing twelve-month return on equity of 45.72%.

When did iBio's stock split?

Shares of iBio reverse split on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.16.

How much money does iBio make?

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $34.25 million and generates $2.37 million in revenue each year. The biotechnology company earns $-23,210,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (302) 355-0650, via email at ir@ibioinc.com, or via fax at 302-356-1173.

This page (NYSEAMERICAN:IBIO) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.